Skip to main content Accessibility help
×
Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-27T08:37:32.912Z Has data issue: false hasContentIssue false

12 - Prevention of coronary heart disease in women

from Part III - Disease prevention

Published online by Cambridge University Press:  21 August 2009

Valerie K Ulstad
Affiliation:
West Hennepin County Medical Center, Minneapolis, MN, USA
Jo Ann Rosenfeld
Affiliation:
The Johns Hopkins University
Get access

Summary

Case 1: a 62-year-old woman comes to you as a new patient. She has no complaints but needs preventive care. She smokes one pack of cigarettes per day and is on no medications. She does no regular physical exercise and has a desk job. She has no chronic medical problems. Her blood pressure is 150/90mmHg, and she has a body mass index (BMI) of 38kg/m2 and a waist-to-hip ratio of 1.2. There are no other physical exam abnormalities. You order fasting screening labs, which show total cholesterol of 265mg/dl (6.9 mmol/l), low-density lipoprotein (LDL) 180mg/dl (4.7mmol/l), high-density lipoprotein (HDL) 25mg/dl (0.65mmol/l), triglycerides 300mg/dl (3.4mmol/l), and glucose 180mg/dl.

Case 2: a 65-year-old woman presents for new patient evaluation after a recent hospitalization for an inferior myocardial infarction (MI). She was treated acutely with angioplasty and stent placement in the right coronary artery. She also has a 30% left anterior descending coronary artery lesion and a 20% circumflex lesion. Her ejection fraction is 40%. She has had no further angina and denies symptoms of congestive heart failure. She smokes half a pack of cigarettes per day and proudly tells you this is much less than she used to smoke. She has no other chronic medical problems.

She is taking atenolol, aspirin, and atorvastatin. Her blood pressure is 160/100mmHg, pulse is 90bpm, BMI is 35kg/m2, and the reminder of her examination is unremarkable. In hospital, her cholesterol was 330mg/dl (8.5mmol/l), LDL 190mg/dl (4.9mmol/l), HDL 40 mg/dl (1.0mmol/l), triglycerides 500mg/dl (5.6mmol/l), and hemoglobin A1C 6.0%.[…]

Type
Chapter
Information
Women's Health in Mid-Life
A Primary Care Guide
, pp. 209 - 224
Publisher: Cambridge University Press
Print publication year: 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas: American Heart Association; 2001
European Heart Network. www.ehnheart.org/statistics/summary. Accessed September 23, 2002
Verma, S. and Anderson, T. J.Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002; 105:546–9CrossRefGoogle ScholarPubMed
Lerner, D. J. and Kannel, W. B.Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am. Heart J. 1986; 111:383–90CrossRefGoogle ScholarPubMed
Rich-Edwards, J. W., Manson, J. E., Hennekens, C. H and Buring, J. E.The primary prevention of coronary heart disease in women. N. Engl. J. Med. 1995; 332: 1758–66CrossRefGoogle ScholarPubMed
Grundy, S. M., Pasternak, R., Greenland, P., et al.Assessment of cardiovascular risk by use of multiple risk factor equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J. Am. Coll. Cardiol. 1999; 34:1348–59CrossRefGoogle ScholarPubMed
Wilson, P. W. F., D'Agostino, R. B., Levy, D., et al.Prediction of coronary risks using risk factor categories. Circulation 1998; 97:1837–47CrossRefGoogle ScholarPubMed
www.statcoder.com. Accessed September 23, 2002
www.nhlbi.nih.gov/health/public/heart/other/hhw/index.htm. Accessed September 23, 2002
Willett, W. C., Green, A., Stampfer, M. J., et al.Relative and absolute excess risk of coronary heart disease among women who smoke cigarettes. N. Engl. J. Med. 1987; 317:1303–9CrossRefGoogle ScholarPubMed
Ockene, I. S. and Miller, N. H.Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. Circulation 1997; 96:3243–7CrossRefGoogle ScholarPubMed
Mosca, L., Grundy, S., Judelson, D., et al.Guide to preventive cardiology for women. AHA/ACC Scientific statement: consensus panel statement. J. Am. Coll. Cardiol. 1999; 33:1751–5Google ScholarPubMed
The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch. Intern. Med. 1997; 157:2413–46CrossRef
Moser, M., Hebert, P. and Hennekens, C. H.An overview of the meta-analyses of the hypertension treatment trials. Arch. Intern. Med. 1991; 151:1277–9CrossRefGoogle ScholarPubMed
Labarthe, D. and Ayala, C.Non-drug interventions in hypertension prevention and control. Cardiol. Clin. 2002; 20:249–63CrossRefGoogle Scholar
Grundy, S. M., Howard, B., Smith, S., et al.Prevention conference VI: diabetes and cardiovascular disease. Executive summary. Conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2002; 105:2231–9CrossRefGoogle ScholarPubMed
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J. Am. Med. Assoc. 2001; 285:2486–97CrossRef
Ford, E. S., Giles, W. H. and Dietz, W. H.Prevalence of the metabolic syndrome among U.S. adults: findings from the third National Health and Nutrition Survey. J. Am. Med. Assoc. 2002; 287:356–9CrossRefGoogle Scholar
Lemaitre, R. N., Psaty, B. M., Heckbert, S. R., et al.Therapy with hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults – evidence from the cardiovascular health study. Arch. Intern. Med. 2002; 162:1395–400CrossRefGoogle ScholarPubMed
Downs, J. R., Clearfield, M., Weis, S., et al.Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/Tex CAPS. J. Am. Med. Assoc. 1998; 279:1615–22CrossRefGoogle Scholar
Sacks, F. M., Pfeffer, M. A., Moye, L. A., et al.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: cholesterol and recurrent events trial investigators. N. Engl. J. Med. 1996; 335:1001–9CrossRefGoogle ScholarPubMed
Packard, C. J.Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 87: 1440–45Google Scholar
LaRosa, J. C., He, J. and Vupputuri, S.Effect of statins on the risk of coronary disease: a meta-analysis of randomized controlled trials. J. Am. Med. Assoc. 1999; 282:2340–46CrossRefGoogle ScholarPubMed
Yeung, A. C. and Tsao, P.Statin therapy: beyond cholesterol lowering and anti-inflammatory effects. Circulation 2002; 105:2937–38CrossRefGoogle Scholar
Pasternak, R. C., Smith, S. C. Jr, Bairey-Merz, C. N., et al.ACC/AHA/NHLBI advisory on the use and safety of statins. J. Am. Coll. Cardiol. 2002; 40:567–72CrossRefGoogle ScholarPubMed
Field, A. E., Coakley, E. H., Must, A., et al.Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch. Intern. Med. 2001; 161:1581–6CrossRefGoogle ScholarPubMed
Manson, J. E., Stampfer, M. J., Colditz, G. A., et al.A prospective study of obesity and the risk of coronary heart disease in women. N. Engl. J. Med. 1990; 322:882–9CrossRefGoogle ScholarPubMed
Eckel, R. H.Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1997; 96:3248–50CrossRefGoogle ScholarPubMed
Bjorntorp, P.Regional patterns of fat distribution. Ann. Intern. Med. 1985; 103: 994–5CrossRefGoogle ScholarPubMed
Lemaitre, R. N., Heckbert, S. R., Psaty, B. M. and Siscovick, D. S.Leisure-time physical activity and the risk of nonfatal myocardial infarction in postmenopausal women. Arch. Intern. Med. 1995; 155:2302–8CrossRefGoogle ScholarPubMed
Kushi, L. H., Fee, R. M., Folsom, A. R., et al.Physical activity and mortality in postmenopausal women. J. Am. Med. Assoc. 1997; 277:1287–92CrossRefGoogle ScholarPubMed
Fletcher, G. F., Balady, G., Blair, S. N., et al.Statement on exercise: benefits and recommendations for physical activity programs for all Americans. A statement for healthcare professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart Association. Circulation 1996; 94:857–62CrossRefGoogle Scholar
Physical activity and cardiovascular health. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health. J. Am. Med. Assoc. 1996; 276:241–6CrossRef
US Department of Health and Human Services. Physical Activity and Health: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Public Health Service, CDC, National Center for Chronic Disease Prevention and Health Promotion; 1996
Manson, J. E., Stampfer, M. J., Colditz, G. A., et al.A prospective study of aspirin use and primary prevention of cardiovascular disease in women. J. Am. Med. Assoc. 1991; 266:521–7CrossRefGoogle ScholarPubMed
US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann. Intern. Med. 2002; 136:157–60CrossRef
Lauer, M.Aspirin for the primary prevention of coronary events. N. Engl. J. Med. 2002; 346:1468–74Google ScholarPubMed
Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. 1994; 308:81–106CrossRef
Hennekens, C. H., Dyken, M. L. and Fuster, V.Aspirin as a therapeutic agent in cardiovascular disease. A statement for health care professionals from the American Heart Association. Circulation 1997; 96:2751–3CrossRefGoogle Scholar
Smith, S. C., Blair, S. N., Bonow, R. O., et al.AHA/ACC Guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. Circulation 2001; 104:1577–9CrossRefGoogle ScholarPubMed
Frishman, W. H. and Cheng, A.Secondary prevention of myocardial infarction: role of beta-adrenergic blockers and angiotensin-converting enzyme inhibitors. Am. Heart J. 1999; 137:S25–34CrossRefGoogle ScholarPubMed
Gheorghiade, M. and Golstein, S.Beta blockers in the post-myocardial infarction patient. Circulation 2002; 106: 394–8CrossRefGoogle ScholarPubMed
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994; 344:1383–9
Lewis, S. J., Sacks, F. M., Mitchell, J. S., et al.Effect of pravastatin on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) Trial. J. Am. Coll. Cardiol. 1998; 32:140–46CrossRefGoogle ScholarPubMed
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 1998; 339:1349–57CrossRef
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360:7–22CrossRef
The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 2000; 342:145–53CrossRef
Yusuf, S.Two decades of progress in preventing vascular disease. Lancet 2002; 360:2–3CrossRefGoogle ScholarPubMed
American College of Cardiology and American Heart Association Task Force on Practice Guidelines. ACC/AHA guidelines for the management of patients with acute myocardial infarction. www.acc.org/clinical/guidelines/nov96/1999/index.htm. Accessed September 23, 2002
Mosca, L., Manson, J. E., Sutherland, S. E., et al.Cardiovascular disease in women. A statement for healthcare professionals from the American Heart Association. Circulation 1997; 96:2468–82CrossRefGoogle ScholarPubMed
DeLorgeril, M., Salen, P., Martin, J. L., et al.Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99:779–85CrossRefGoogle Scholar
American Heart Association. www.americanheart.org. Accessed September 23, 2002
Boushey, C. J., Beresford, S. A. A., Omenn, G. S. and Motulsky, A. G.A quantitative assessment of plasma homocysteine as a risk factor for vascular disease; probable benefits of increasing folic acid intakes. J. Am. Med. Assoc. 1995; 274:1049–57CrossRefGoogle ScholarPubMed
Nygard, O., Nordrehaug, J. E., Refsum, H., et al.Plasma homocysteine levels and mortality in patients with coronary artery disease. N. Engl. J. Med. 1997; 337:230–36CrossRefGoogle ScholarPubMed
Malinow, M. R., Bostom, A. G., Krauss, R. M.Homocysteine, diet and cardiovascular diseases: a statement for health care professionals from the nutrition committee, American Heart Association. Circulation 1999; 99:178–82CrossRefGoogle Scholar
Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Br. Med. J. 1998; 316:894–8CrossRef
Schnyder, G., Roffi, M., Flammer, Y., Pin, R. and Hess, O. M.Effect of homocysteine-lowering therapy with folic acid, vitamin B 12, and vitamin B 6 on clinical outcomes after percutaneous coronary intervention: the Swiss Heart Study: a randomized controlled trial. J. Am. Med. Assoc. 2002; 288:973–9CrossRefGoogle Scholar
Grady, D., Herrington, D., Bittner, V., et al.Cardiovascular disease outcomes during 6.8 years of hormone replacement therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). J. Am. Med. Assoc. 2002; 288:49–57CrossRefGoogle Scholar
Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results form the Women's Health Initiative randomized controlled trial. J. Am. Med. Assoc. 2002; 288:321–33CrossRef

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×